Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients
Christopher G. Willett(Duke Medical Center), Yves Boucher(Harvard University), Dan G. Duda(Harvard University), Emmanuelle di Tomaso(Harvard University), Lance L. Munn(Harvard University), Ricky T. Tong(Harvard University), Sergey V. Kozin(Harvard University), Lucine Petit(Harvard University), Rakesh K. Jain(Harvard University), Daniel C. Chung(Harvard University), Dushyant V. Sahani(Harvard University), Sanjeeva P. Kalva(Harvard University), Kenneth S. Cohen(Harvard University), David T. Scadden(Harvard University), Alan J. Fischman(Harvard University), Jeffrey W. Clark(Harvard University), David P. Ryan(Harvard University), Andrew X. Zhu(Harvard University), Lawrence S. Blaszkowsky(Harvard University), Paul C. Shellito(Harvard University), Mari Mino–Kenudson(Harvard University), Gregory Y. Lauwers(Harvard University)
Cited by 419Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis